Charles River Laboratories (CRL) Tops Q3 EPS by 8c; Narrows Outlook

Charles River Laboratories (NYSE: CRL) reported Q3 EPS of $1.30, $0.08 better than the analyst estimate of $1.22. Revenue for the quarter came in at $464.2 million versus the consensus estimate of $458.72 million.

GUIDANCE:

Charles River Laboratories sees FY2017 EPS of $5.08-$5.18, versus prior $5.00-$5.15 and the consensus of $5.10.

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Movano (MOVE) Misses Q2 EPS by 195c